WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/016611    International Application No.:    PCT/JP2017/026391
Publication Date: 25.01.2018 International Filing Date: 21.07.2017
C07C 255/59 (2006.01), A61K 31/197 (2006.01), A61K 31/277 (2006.01), A61K 31/382 (2006.01), A61P 27/06 (2006.01), C07C 229/38 (2006.01), C07D 311/68 (2006.01), C07D 333/16 (2006.01)
Applicants: TOA EIYO LTD. [JP/JP]; 10-6, Hatchobori 3-chome, Chuo-ku, Tokyo 1040032 (JP)
Inventors: SAWABE, Toshihiro; (JP).
MARUYAMA, Fumito; (JP).
TAKAYA, Akiyuki; (JP).
HASEGAWA, Takeshi; (JP)
Agent: THE PATENT CORPORATE BODY ARUGA PATENT OFFICE; Sawanotsuru Ningyocho Bldg., 1-3-8, Nihonbashi Ningyocho, Chuo-ku, Tokyo 1030013 (JP)
Priority Data:
2016-144392 22.07.2016 JP
(JA) 緑内障治療薬
Abstract: front page image
(EN)Provided is a novel therapeutic agent for glaucoma, which has an sGC-activating activity. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an active ingredient, a compound represented by formula (I-a) or formula (I-b) and having a LogD value of 1.5 to 2.5 exclusive or a pharmaceutically acceptable salt of the compound. [In formulae (I-a) and (I-b), each symbol is as defined in the description.]
(FR)L'invention concerne un nouvel agent thérapeutique pour le glaucome, qui a une activité d'activation de sGC. Un agent thérapeutique pour le glaucome ou un agent hypotensif oculaire, qui contient, en tant qu'ingrédient actif, un composé représenté par la formule (I-a) ou la formule (I.b) et ayant une valeur exclusive du LogD de 1,5 à 2,5, ou un sel pharmaceutiquement acceptable du composé. [Dans les formules (I-a) et (I-b), chaque symbole est tel que défini dans la description.]
(JA)sGC活性化作用を有する新たな緑内障治療薬の提供。 式(I-a)または式(I-b)で表されるLogD値が1.5より大きく2.5未満である化合物又はその製薬学的に許容される塩を有効成分として含有する緑内障治療薬又は眼圧降下剤。[式(I-a)および(I-b)中の記号は、明細書中の意味を示す。]
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)